specific driver mutation manages shrink tumor leaves cell resistant drug cell proliferate create additional tumors unresponsive medicine certain cancers true hiv need treated multiple drugs drug added come costs potential effects researchers need figure optimal strategies rarity somatic mutations slows transition laboratory clinic mutations occur 1 percent patients certain type cancer evaluating drug possibly address mutation requires clinical trial finding patients willing able enroll study long time challenges spurring research methods drug designs infrastructure meant hasten expansion precision genetic medicine approaches taking account new realization traditionally cancer defined location arose body example breast lung turns mutations known drive particular type